The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Underw Regulatory News (HUW)

Share Price Information for Helios Underw (HUW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 165.00
Bid: 160.00
Ask: 170.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.25%)
Open: 165.00
High: 165.00
Low: 165.00
Prev. Close: 165.00
HUW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reinsurance Agreement

26 Jul 2013 11:21

RNS Number : 2468K
Hampden Underwriting Plc
26 July 2013
 



26 July 2013

 

Hampden Underwriting PLC

("Hampden Underwriting" or the "Company")

 

Reinsurance releases capital for reinvestment in new opportunities

 

Hampden Underwriting, which provides investors with a limited liability direct investment into the Lloyd's insurance market, is pleased to announce the significant release of capital achieved by way of an annually renewable reinsurance arrangement.

 

Overview of the transaction

 

§ Collateralised quota share reinsurance agreement commencing with 2013 year of account

§ 50% of the Company's 2013 insurance exposure ceded to reinsurer

§ Release of £4.1m (approximately 50%) of the Company's £8.2m of Funds at Lloyd's) for reinvestment in new opportunities

§ Ratcheted, performance-based profit commission payable to the Company of between 10% and 20% of the profits arising on business ceded in each period

§ Minimum term of one year renewable annually thereafter

 

 

Commenting upon this transaction Sir Michael Oliver, the Company's Chairman, said:

"This transaction presents Hampden Underwriting with a welcome source of capital with which to fund near-term opportunities the Company wishes to pursue and does so on attractive commercial terms. The Board regularly considers the relative merits of alternative sources of capital and is confident that this is an appropriate funding option at this time."

 

Commenting upon this transaction Nigel Hanbury, the Company's Chief Executive, said:

 

"Current market conditions continue to present the Company with attractive investment opportunities which require funding. We are delighted to have been able to successfully conclude this transaction which provides the Company with a modest war chest with which we can continue to progress acquisition opportunities. The reinsurance terms provide a profit commission in good underwriting years and a reduced risk exposure in disappointing underwriting years in a spectrum that is both equitable and commercially attractive. Its annually renewable feature provides Hampden Underwriting with certainty for 2013 as well as the appropriate opportunity to review the arrangement from time to time."

 

 

 

For further information please contact:

Hampden Underwriting

 

Nigel Hanbury

nigel.hanbury@hampdenplc.com

Smith & Williamson Corporate Finance

 

David Jones

020 7131 4000

 

Additional information on the reinsurance arrangements

The Company has entered a reinsurance agreement with Hampden Insurance PCC (Guernsey) Limited - Cell 6 ("Cell 6"), a newly-formed special purpose vehicle. On a back-to-back basis, Cell 6 has reinsured the reinsurance risk with Bermudan reinsurer, XL Re Ltd ("XL"), part of global NYSE-quoted insurer XL Group plc.

 

The key terms of the arrangements are as follows:

- XL will take on via Cell 6 the risks and rewards of 50% of the Company's existing 2013 underwriting activities (although the activities themselves and the underwriting capacity will remain the Company's);

- XL will provide a letter of credit to Lloyd's in an amount of £4.1m (approximately 50% of the Company's existing funds at Lloyd's ("FAL"), enabling an equivalent amount to be released from FAL to the Company;

- XL will pay a profit commission of between 10% and 20% of profits from the business ceded to the Company (via Cell 6) depending on the results of the relevant insurance years of account;

- XL will pay a fee to Cell 6 of 1.5% per year of account of the value of the letter of credit provided to Lloyd's and Cell 6 will pay this on to the Company, less the Company's share of Cell 6's management fees, costs and expenses which is estimated to be approximately £12,500 per annum; and

- the reinsurance arrangements apply to the Company's 2013 year of account and are renewable annually thereafter.

 

Cell 6 is ultimately 51% owned by Nigel Hanbury (a director and 14.8% shareholder in the Company) and 49% by Hampden Capital plc (a 11.9% shareholder in the Company). Nigel Hanbury and a number of Lloyd's underwriting entities ultimately owned by him and his family have entered reinsurance agreements with Cell 6 on a pari passu basis. The terms of the transaction have been approved by the independent members of the Company's board of directors.

 

 

About Hampden Underwriting plc

Hampden Underwriting plc has been incorporated primarily to provide a limited liability direct investment into the Lloyd's insurance market. Hampden Underwriting plc is quoted on the London Stock Exchange's AIM market (ticker: HUW). For further information please visit www.hampdenplc.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUNARROBABUAR
Date   Source Headline
11th May 20217:00 amRNSHolding(s) in Company
27th Apr 202112:57 pmEQSHardman & Co Research : Hardman & Co Video Event | Helios Underwriting Plc - Investor Forum
27th Apr 20217:00 amRNSHolding(s) in Company
21st Apr 20217:00 amRNSDirectorate Changes
20th Apr 202111:35 amRNSHolding(s) in Company
1st Apr 202112:34 pmRNSResult of GM, TVR and Directors' Participation
1st Apr 20217:00 amRNSQuarterly Syndicate Mid-point Forecasts
30th Mar 20217:00 amRNSResult of Open Offer
11th Mar 20217:00 amRNSDirector/PCA Shareholding
9th Mar 20217:00 amRNSResult of Placing and Subscription
8th Mar 20214:45 pmRNSFundraising to raise up to approximately £60m
16th Feb 20211:37 pmRNSRevision to Adjusted Net Asset Value
8th Feb 20217:00 amRNSDirectorate Change
2nd Feb 20217:00 amRNSDirector/PDMR Shareholding
18th Jan 20217:00 amRNSAppointment of Financial Adviser
1st Dec 20207:00 amRNSHolding(s) in Company
1st Dec 20207:00 amRNSHolding(s) in Company
1st Dec 20207:00 amRNSMaterial Capacity Increase
30th Nov 20209:57 amRNSHolding(s) in Company
30th Nov 20207:00 amRNSHolding(s) in Company
30th Nov 20207:00 amRNSHolding(s) in Company
26th Nov 20203:40 pmRNSResult of GM, TVR and Directors' Participations
24th Nov 20207:00 amRNSResult of Open Offer
19th Nov 20207:00 amRNSQuarterly Syndicate Mid-Point Forecasts
2nd Nov 20207:00 amRNSPlacing, Subscription, Open Offer & Acquisitions
7th Oct 20207:00 amRNSProposed Fundraising
25th Sep 20207:00 amRNSHalf-year Report
17th Aug 20207:00 amRNSQuarterly Syndicate Mid-Point Forecasts
10th Aug 20207:00 amRNSUpdate on Capacity and Growth Plans
25th Jun 202012:38 pmRNSResult of AGM
3rd Jun 20207:00 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 202012:28 pmRNSHolding(s) in Company
1st Jun 20207:30 amRNSDirector/PDMR Shareholding
29th May 20207:00 amRNSFinal results for the year ended 31 December 2019
30th Mar 20207:00 amRNSQuarterly Syndicate Mid-point Forecasts
29th Jan 20207:00 amRNSCapacity Update and Transaction in Own Shares
13th Dec 20197:00 amRNSAcquisition
18th Nov 20197:00 amRNSQuarterly Syndicate Mid-point Forecasts
7th Oct 20197:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Sep 20199:39 amRNSReplacement- Transaction in Own Shares
2nd Sep 20197:00 amRNSTransaction in Own Shares and Total Voting Rights
19th Aug 20197:00 amRNSTransaction in Own Shares
16th Aug 20197:00 amRNSQuarterly Syndicate Mid-point Forecasts
15th Aug 20194:28 pmRNSHolding(s) in Company
12th Aug 20197:00 amRNSProposed Ordinary Share repurchases
19th Jul 20198:47 amRNSHolding(s) in Company
16th Jul 20191:00 pmRNSResult of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.